IMMORNA
LIVE

Serial Number

97424017

Owner

Immorna Biotherapeutics Inc.

Attorney

Keith Toms, Esq.

Filing Date

May 23, 2022

Add to watchlist:

No watchlists yet
View on USPTO

IMMORNA Trademark

Serial Number: 97424017

IMMORNA is a trademark filed by Immorna Biotherapeutics Inc. on May 23, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Immorna Biotherapeutics Inc.

635 Davis Drive, Suite 400
Morrisville, NC 27560

Entity Type: 03

Trademark Details

Filing Date

May 23, 2022

Registration Date

Not Registered

Published for Opposition

October 31, 2023

Goods & Services

Reagents for scientific, research, and medical research use; chemical reagents other than for medical purposes; diagnostic reagents for clinical or medical laboratory use; mRNA reagents for scientific, research, and medical research use; reagents comprised of nanoparticles for scientific, research, and medical research use; reagents, comprised of capsids for scientific, research, and medical research use

Messenger RNA (mRNA) pharmaceutical and biopharmaceutical preparations for use in the treatment of oncological diseases and disorders, infectious diseases, autoimmune and genetic diseases and disorders, and for use in medical cosmetology; messenger RNA (mRNA) pharmaceutical and biopharmaceutical preparations for vaccines; Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; Pharmaceutical preparations and substances for the treatment of infectious diseases; vaccines; pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparation and substances for the treatment of genetic disorders; pharmaceutical preparations and substances for use in medical cosmetology; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic preparations for medical purposes for detecting the presence of tumors, infectious diseases, genetic disorders and autoimmune disorders and conditions; drug delivery agents in the form of polymer and lipid nanoparticles for delivery of mRNA being a pharmaceutical preparation; drug delivery agents in the form of nanoparticles and capsids for delivery for a wide variety of therapeutic agents

Manufacture of nanoparticles and capsids for use in connection with mRNA-based therapeutics for others

Research and development of messenger RNA (mRNA) biotechnologies; Research and development services in the field of biologics, including but not limited to mRNA, RNA, DNA, antibodies, vaccines, and peptides; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostic services for scientific research purposes, and pharmacogenetics; conducting research and clinical trials for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostic services for scientific research purposes, and pharmacogenetics; Scientific research, namely, mRNA synthesis, purification and testing

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 23, 2025 EXRA
SOU EXTENSION 4 GRANTED
Dec 22, 2025 EX4G
SOU EXTENSION 4 FILED
Dec 22, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Dec 22, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 25, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jun 24, 2025 EX3G
SOU EXTENSION 3 FILED
Jun 24, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 2 GRANTED
Dec 20, 2024 EX2G
SOU EXTENSION 2 FILED
Dec 20, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 20, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 25, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jun 25, 2024 EX1G
SOU EXTENSION 1 FILED
Jun 25, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 24, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 26, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 31, 2023 NPUB
PUBLISHED FOR OPPOSITION
Oct 31, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 11, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 21, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 21, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 21, 2023 CRFA
ASSIGNED TO LIE
Sep 20, 2023 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 2, 2023 TROA
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Mar 21, 2023 GEAN
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Mar 21, 2023 GEAP
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Mar 21, 2023 EPEN
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Mar 21, 2023 CPEA
ASSIGNED TO EXAMINER
Mar 10, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 26, 2022 NWOS
NEW APPLICATION ENTERED
May 26, 2022 NWAP